TickerFacts.

Company research / VTVT

vTv Therapeutics Inc. (VTVT)

Build a valuation ↗↓ Download CSV

CIK 0001641489 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, vTv Therapeutics Inc. reported revenue of $0. Revenue fell 100.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $36.84M.

Key ratios (year ended 2025-12-31)

-41.9%
Return on year-end equity
-100.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$36.84M$0$1.02M$0$2.02M$4.00M$6.41M$2.76M$12.43M$291.0K$634.0K
R&D Expense$28.68M$17.86M$11.55M$13.60M$12.36M$13.32M$11.02M$15.12M$23.04M$39.64M$44.95M
Operating Income-$9.25M-$32.81M-$24.18M-$25.50M-$22.54M-$21.66M-$11.85M-$20.89M-$19.82M-$50.68M-$55.02M
Net Income-$4.76M-$26.97M-$18.46M-$20.25M-$19.16M-$12.99M-$8.50M-$13.04M-$7.91M-$16.14M-$16.35M
Total Assets$87.59M$89.90M$38.27M$11.02M$33.24M$25.47M$14.79M$9.27M$8.56M$27.92M$54.49M
Total Liabilities$8.96M$25.46M$23.96M$29.57M$27.40M$10.25M$11.00M$18.11M$28.93M$47.52M$22.93M
Long-Term Debtn/an/an/an/an/an/an/a$5.04M$15.11Mn/a$11.06M
Shareholders' Equity$78.63M$64.44M$12.20M-$24.68M-$10.74M-$9.74M-$80.10M-$49.02M-$82.85M-$151.05M-$90.94M
Cash & Equivalents$86.64M$88.93M$36.75M$9.45M$12.13M$13.41M$5.75M$1.78M$1.68M$11.76M$51.51M
Operating Cash Flow-$16.76M-$25.25M-$25.31M-$19.08M-$16.02M-$19.31M-$18.00M-$23.02M-$26.86M-$44.56M-$48.21M
Capital Expendituresn/an/a$0$0$21.0K$0$0$70.0K$5.0K$57.0K$87.0K
Free Cash Flown/an/a-$25.31M-$19.08M-$16.04M-$19.31M-$18.00M-$23.09M-$26.86M-$44.62M-$48.30M

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView